VolitionRx (NYSE: VNRX)

Currency in USD

Last close As at 30/11/2023


−0.01 (−1.30%)

Market capitalisation


VolitionRx is a clinical diagnostics company developing easy-to-use and cost-effective blood tests to diagnose a range of diseases in humans and animals including sepsis and cancer. Diagnostic Nu.Q tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid.

Latest Insights

View More

Healthcare | edison tv

Volition Webinar: Unraveling the web of NETs in sepsis

Healthcare | edison tv

VolitionRx webinar: Unravelling the web of NETs in sepsis

Healthcare | edison tv

Executive interview: Volition FY22 earnings



Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Cameron Reynolds


  • Jake Micallef

    Chief Scientific Officer

  • Scott Powell

    Director of IR

  • Terig Hughes


Balance Sheet

Forecast net debt (US$m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual (4.3) (39.4) (64.2)
Relative (13.5) (40.1) (68.9)
52 week high/low US$2.7/US$0.6


While pets are increasingly being ‘humanized’, their healthcare has lagged advancements seen on the human side. With the COVID-19 pandemic accelerating the trend of pet ownership, demand for improved care in a market with limited alternatives has triggered the need for newer-generation pet diagnostics. VolitionRx, a diagnostics company focused on sepsis and cancer detection, has pioneered a low-cost, quick-turnaround, cancer screening and monitoring tool for companion animals (Nu.Q Vet), an adaption of its core nucleosome quantification (Nu.Q) platform on the human side. With supply and distribution deals with leading veterinary diagnostics players IDEXX and Heska already signed, Nu.Q Vet has the building blocks in place to evolve into a potential disrupter in the space.

Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (c) P/E (x) P/CF (x)
2018A 0.0 (17.9) (18.0) (57.37) N/A N/A
2019A 0.0 (16.1) (16.1) (41.09) N/A N/A
2020E 0.0 (17.2) (17.4) (42.61) N/A N/A
2021E 0.1 (18.6) (18.8) (44.46) N/A N/A

Further insights



Volition: Views from the sharp end



Healthcare Week 2023

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Read latest





VolitionRx – Decoding the DNA of cancer 

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free